NCT03179930View on ClinicalTrials.gov

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
LymphomaRelapsedRefractory
Interventions
DRUG

Entinostat

All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15

DRUG

Pembrolizumab

pembrolizumab 200 mg IV on D1

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

60208

Northwestern University (Data Collection Only), Evanston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

14263-0001

Roswell Park Cancer Institute (Data Collection Only), Buffalo

Sponsors

Collaborators (1)

Syndax Pharmaceuticals
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Syndax Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER